Development of in-House Synthesis and Quality Control of [<sup>99m</sup>Tc]Tc-PSMA-I&S
Many radioactive PSMA inhibitory substances have already been developed for PET diagnostics and therapy of prostate cancer. Because PET radionuclides and instrumentation may not be available, technetium-99 m labelled tracers can be considered as a diagnostic alternative. A suitable tracer is [<su...
Main Authors: | Elisabeth Plhak, Christopher Pichler, Edith Gößnitzer, Reingard M. Aigner, Herbert Kvaternik |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/28/2/577 |
Similar Items
-
Preparation and Biological Evaluation of [<sup>99m</sup>Tc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer
by: Di Xiao, et al.
Published: (2020-11-01) -
Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
by: Jarosław B. Ćwikła, et al.
Published: (2021-10-01) -
[<sup>99m</sup>Tc]Tc-iFAP Radioligand for SPECT/CT Imaging of the Tumor Microenvironment: Kinetics, Radiation Dosimetry, and Imaging in Patients
by: Luis Coria-Domínguez, et al.
Published: (2022-05-01) -
Genotoxicity Associated with <sup>131</sup>I and <sup>99m</sup>Tc Exposure in Nuclear Medicine Staff: A Physical and Biological Monitoring Study
by: Justyna Miszczyk, et al.
Published: (2022-05-01) -
[<sup>99m</sup>Tc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities
by: Paola Vallejo-Armenta, et al.
Published: (2022-06-01)